Department of Veterinary and Biomedical Sciences, The Pennsylvania State University, Center for Molecular Toxicology and Carcinogenesis, University Park, Pennsylvania 16802, USA.
J Biol Chem. 2010 Aug 6;285(32):24388-97. doi: 10.1074/jbc.M110.118570. Epub 2010 May 28.
The aryl hydrocarbon receptor (AHR) is the ligand-activated transcription factor responsible for mediating the toxicological effects of dioxin and xenobiotic metabolism. However, recent evidence has implicated the AHR in additional, nonmetabolic physiological processes, including immune regulation. Certain tumor cells are largely nonresponsive to cytokine-mediated induction of the pro-survival cytokine interleukin (IL) 6. We have demonstrated that multiple nonresponsive tumor lines are able to undergo synergistic induction of IL6 following combinatorial treatment with IL1beta and the AHR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin. Such data implicate the AHR in tumor expansion, although the mechanistic basis for the AHR-dependent synergistic induction of IL6 has not been determined. Here, we demonstrate that ligand-activated AHR is involved in priming the IL6 promoter through binding to nonconsensus dioxin response elements located upstream of the IL6 start site. Such binding appears to render the promoter more permissive to IL1beta-induced binding of NF-kappaB components. The nature of the AHR-dependent increases in IL6 promoter transcriptional potential has been shown to involve a reorganization of repressive complexes as exemplified by the presence of HDAC1 and HDAC3. Dismissal of these HDACs correlates with post-translational modifications of promoter-bound NF-kappaB components in a time-dependent manner. Thus the AHR plays a role in derepressing the IL6 promoter, leading to synergistic IL6 expression in the presence of inflammatory signals. These observations may explain the association between enhanced expression of AHR and tumor aggressiveness. It is likely that AHR-mediated priming is not restricted to the IL6 promoter and may contribute to the expression of a variety of genes, which do not have consensus dioxin response elements.
芳香烃受体 (AHR) 是配体激活的转录因子,负责介导二恶英和外源物质代谢的毒理学效应。然而,最近的证据表明 AHR 参与了其他非代谢的生理过程,包括免疫调节。某些肿瘤细胞对细胞因子介导的促生存细胞因子白细胞介素 (IL) 6 的诱导几乎没有反应。我们已经证明,在联合使用白细胞介素 1β和 AHR 激动剂 2,3,7,8-四氯二苯并对二恶英处理后,许多无反应的肿瘤系能够协同诱导 IL6。这些数据表明 AHR 参与了肿瘤的扩张,尽管 AHR 依赖性协同诱导 IL6 的机制基础尚未确定。在这里,我们证明配体激活的 AHR 通过与位于 IL6 起始位点上游的非共识二恶英反应元件结合,参与 IL6 启动子的启动。这种结合似乎使启动子更容易与 NF-κB 成分的 IL1β诱导结合。已经表明,AHR 依赖性增加 IL6 启动子转录潜力的性质涉及抑制复合物的重新组织,如存在 HDAC1 和 HDAC3 所示。这些 HDAC 的解雇与 NF-κB 成分在启动子上的翻译后修饰呈时间依赖性相关。因此,AHR 在解除 IL6 启动子的抑制中发挥作用,导致在炎症信号存在下协同表达 IL6。这些观察结果可能解释了 AHR 表达增强与肿瘤侵袭性之间的关联。AHR 介导的启动可能不仅限于 IL6 启动子,并可能有助于各种基因的表达,这些基因没有共识的二恶英反应元件。